All products are for laboratory research use only. Not for human consumption.
Metabolic
The Triple Agonist
RM 650
Command your metabolic fire. Retatrutide 20mg activates a triple-action pathway, redefining your relationship with energy and effortless control.
For research use only. Not for human or veterinary consumption. This product is not a medicine and is not intended to diagnose, treat, cure or prevent any disease.
Overview
Retatrutide is the only triple agonist of GLP-1, GIP, and Glucagon receptors in active clinical development. In Phase 2, the 12mg dose achieved 24.2% mean body weight reduction at 48 weeks — a figure never previously achieved by any pharmaceutical in a controlled weight loss trial.
Mechanism of action
Primary appetite suppression and glucose control
Augments and synergizes with GLP-1 receptor activation
The unique third receptor absent from all currently approved agents
Key finding Retatrutide achieved 24.2% mean body weight reduction at 48 weeks (12mg dose, Phase 2) — approximately 2x the magnitude of semaglutide (Wegovy) at its 68-week trial endpoint, achieved in 20 fewer weeks.
Key research findings
Mean body weight reduction at 48 weeks in Phase 2 trial, 12mg dose group (n=48)
Jastreboff AM et al. N Engl J Med, 2023Duration to achieve 24.2% weight loss — 20 weeks fewer than semaglutide needed for 14.9%
Phase 2 NCT04881760Of the top dose group lost at least 5% body weight — vs 69% for semaglutide
Jastreboff AM et al. N Engl J Med, 2023Active Phase 3 program initiated — FDA IND granted for obesity indication
ClinicalTrials.gov NCT05394519Research areas
The most potent pharmacological weight loss mechanism ever studied — triple receptor activation drives a genuinely unprecedented magnitude of fat loss.
Phase 2 data showed significant improvements in triglycerides, LDL, and cardiovascular risk markers alongside weight loss.
Glucagon receptor activation uniquely drives hepatic lipid reduction — relevant to NAFLD/NASH research independent of weight loss.
Triple receptor pharmacology offers unique tools for studying GLP-1, GIP, and Glucagon receptor interactions and downstream signaling.
Safety profile
Phase 2 safety profile was consistent with the GLP-1 class — primarily GI effects during dose titration. The glucagon component adds hepatic considerations.
Nausea, vomiting, diarrhea — consistent with GLP-1 class, primarily during titration
Glucose-dependent insulin release — hypoglycemia risk low but possible in fasted states
Mild heart rate increase (2-4 bpm) — consistent with GLP-1 class
Glucagon receptor activation — monitor liver enzymes in sensitive models
Molecular profile
Frequently asked questions
Tirzepatide is a dual GLP-1 + GIP agonist, approved for type 2 diabetes and obesity. Retatrutide adds a third receptor — glucagon. The glucagon receptor uniquely increases energy expenditure and hepatic lipid clearance, mechanisms entirely absent from tirzepatide. This additional pathway is believed to explain the superior weight loss magnitude.
Yes. It comes from a peer-reviewed Phase 2 randomized controlled trial published in the New England Journal of Medicine (Jastreboff AM et al., 2023). The trial enrolled 338 participants randomized to placebo or multiple dose cohorts. The 24.2% figure is the mean at 48 weeks in the 12mg dose group.
Eli Lilly initiated Phase 3 trials (NCT05394519) in 2023. Given typical Phase 3 timelines of 2-3 years plus regulatory review, approval could occur as early as 2026-2027, though this is speculative. The compound is currently available only for research purposes.
Glucagon traditionally raises blood sugar and is considered catabolic. However, at the doses used in Retatrutide, glucagon receptor activation primarily affects hepatic lipid metabolism and thermogenesis — it increases calorie burning and clears liver fat. When combined with GLP-1 and GIP (which control the insulin response), the blood sugar effects are counterbalanced while the fat-burning effects are additive.
Semaglutide 2.4mg (Wegovy) achieves approximately 14.9% weight loss over 68 weeks. Retatrutide achieved 24.2% over 48 weeks — a meaningfully higher magnitude in fewer weeks. Different trial designs and populations apply, but the directional difference is substantial.
The safety profile was consistent with the GLP-1 class: primarily gastrointestinal effects (nausea, vomiting, diarrhea) concentrated during the dose escalation phase. No serious adverse events were considered drug-related. A mild heart rate increase (2-4 bpm) was observed, consistent with GLP-1 class effects.
References
